A first-of-its-kind nanoparticle vaccine candidate for respiratory syncytial virus has been designed in an international research effort.Tags: The Problem Is SolvedIs Homework One WordAssignable CausesIntercultural Communication EssayShort Essay On N MarriageEssays About George MasonEssays In Present TenseSociological Research Paper TopicsPhd Dissertation International Relations
A study of infant feeding practices was carried out on a sample of 100 mother and infant pairs.
The results revealed that only 20% of mothers in the study currently exclusively breastfeed their babies.
As yet no RSV vaccine is ready for use in disease prevention.
"It has historically been challenging to produce an RSV vaccine that is both safe and effective, but exciting new vaccine design strategies continue to emerge," said Brooke Fiala, a research scientist at the University of Washington School of Medicine's Institute for Protein Design and a lead author of the study.
This wasn’t the first time that infant formula had caused illnesses and even deaths to infants worldwide - hence the continuous campaign of World Health Organization (WHO) and UNICEF along with other breastfeeding advocates, for mothers to breastfeed their children at least until 6 months of age.
Infant feeding practices refer generally to meet the nutritional and immunological needs of the baby.It also included scientists from Fred Hutch Cancer Research Center in Seattle, Karolinska Institute in Stockholm, Sweden; Vaccine Formulation Institute in Godalming, United Kingdom; European Virus Bioinformatics Center in Jena, Germany; the Vaccine Formulation Laboratory at the University of Lausanne, Switzerland; and the Institute of Microbiology at the Swiss Federal Institute of Technology (ETH Zu? Several of the Seattle researchers have launched a biotech company called Icosavax to manufacture the RSV vaccine candidate and evaluate it in clinical trials.Icosavax will also apply the nanoparticle platform to design and test vaccines for other infectious diseases.The new vaccine elicits potent neutralizing antibodies against RSV in both mice and monkeys.The animal research findings, reported March 7 in the journal Cell, pave the way for human clinical trials.In the United States, RSV is the leading cause of pneumonia in babies under a year old.According to the National Institute for Allergy and Infectious Disease, RSV is responsible for an estimated 64 million infections and causes 160,000 deaths globally each year.About 99 percent of the RSV deaths occur in developing countries.After considerable research, several vaccine candidates are in preclinical or clinical testing.The project was funded primarily by the Bill and Melinda Gates Foundation, and also by the state of Washington, the Howard Hughes Medical Institute, the Netherlands Organization for Scientific Research, the European Molecular Biology Organisation, the Swedish Research Council, Karolinska Institutet, National Institute of Allergy and Infectious Diseases, National Institute for General Medical Sciences, a Pew Biomedical Scholars Award, and an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund.Introduction The melamine controversy that erupted during the last quarter of year 2008 brought people’s attention back to the debates between breastfeeding and the use of breast milk substitutes like commercial infant formula.